HER2 inhibitors are currently used in HER2-positive carcinomas, including breast, colon, and non-small-cell lung (NSCLC) cancers, Abl inhibitors are used in chronic myeloid leukemia. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.